Eliem Therapeutics Valuation
| ELYMDelisted Stock | USD 3.00 0.08 2.60% |
At this time, the firm appears to be overvalued. Eliem Therapeutics shows a prevailing Real Value of $2.85 per share. The current price of the firm is $3.0. Our model computes the value of Eliem Therapeutics from reviewing the firm fundamentals such as Current Valuation of 122.66 M, shares owned by institutions of 77.67 %, and Shares Owned By Insiders of 10.38 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Eliem Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Eliem Therapeutics is based on 3 months time horizon. Increasing Eliem Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Eliem stock is determined by what a typical buyer is willing to pay for full or partial control of Eliem Therapeutics. Since Eliem Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eliem Stock. However, Eliem Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.0 | Real 2.85 | Hype 3.24 | Naive 3.28 |
The intrinsic value of Eliem Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eliem Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eliem Therapeutics helps investors to forecast how Eliem stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eliem Therapeutics more accurately as focusing exclusively on Eliem Therapeutics' fundamentals will not take into account other important factors: Eliem Therapeutics Total Value Analysis
Eliem Therapeutics is currently anticipated to have valuation of 122.66 M with market capitalization of 346.03 M, debt of 349 K, and cash on hands of 122.95 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Eliem Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
122.66 M | 346.03 M | 349 K | 122.95 M |
Eliem Therapeutics Asset Utilization
One of the ways to look at asset utilization of Eliem is to check how much profit was generated for every dollar of assets it reports. Eliem Therapeutics shows a negative utilization of assets of -0.25 percent, losing $0.002454 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Eliem Therapeutics shows how discouraging it operates for each dollar spent on its assets.Eliem Therapeutics Ownership Allocation
Eliem Therapeutics holds a total of 67.06 Million outstanding shares. The majority of Eliem Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eliem Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eliem Therapeutics. Please pay attention to any change in the institutional holdings of Eliem Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eliem Therapeutics Profitability Analysis
Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0.About Eliem Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Eliem Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eliem Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Eliem Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Eliem Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eliem Therapeutics. We calculate exposure to Eliem Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eliem Therapeutics's related companies.Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. Eliem Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Eliem Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Eliem Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 27 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |